https://www.youtube.com/watch?v=O9ImNvSL0MM
Dr. Hearn Jay Cho of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discusses different immunotherapies used in the treatment of b

https://www.cancerresearch.org/events/webinars/immunotherapy-blood-cancer-myeloma-leukemia
Dr. Hearn Jay Cho of the Mt. Sinai School of Medicine discusses the latest research and developments in cancer immunotherapy for leukemia, lymphoma, and multiple myeloma.

https://www.cancerresearch.org/blog/december-2021/blood-cancer-immunotherapy-hearn-jay-cho
Dr. Hearn Jay Cho, of Mount Sinai Tisch Cancer Institute, answers questions about blood cancer and immunotherapy after the 2021 CRI Virtual Immunotherapy Patient Summit.

https://www.cancerresearch.org/cancer-types/multiple-myeloma
Immunotherapy for multiple myeloma is a promising new treatment, with the potential for long-term cancer remission. ... Hearn Jay Cho, MD, PhD Multiple Myeloma Center of Excellence, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai. ... and activity; often expressed by leukemia, lymphoma, and myeloma cells; CD20:

https://profiles.mountsinai.org/hearn-jay-cho
Hearn Jay Cho, MD, PhD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Dr. Cho specializes in clinical care and research in multiple myeloma and related diseases.

https://ashpublications.org/blood/article/136/22/2491/461665/What-is-the-future-of-immunotherapy-in-multiple
The future is now: Ab immunotherapy is the new backbone of MM therapy. Since the approval of combination therapies containing monoclonal antibodies (mAbs) for patients with relapsed multiple myeloma (MM), the anti-CD38 mAb daratumumab (Dara) has become the new backbone of first-line therapy in transplantation-eligible and -ineligible MM patients.

https://www.onclive.com/view/dr-cho-on-targets-for-immunotherapy-in-multiple-myeloma
Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses current and emerging targets for immunotherapy in the

https://www.onclive.com/view/dr-cho-on-promising-combinations-in-multiple-myeloma
Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

https://blog.dana-farber.org/insight/2019/07/immunotherapy-what-it-is-how-it-works-and-current-research/
NK cell therapy is being tested in many forms of cancer, including leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, and pancreatic cancer. Potential side effects Like virtually all cancer therapies, immunotherapies carry the potential for side effects.

https://www.sciencedaily.com/releases/2022/11/221104100247.htm
Researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.

https://news.med.miami.edu/multiple-myeloma-immunotherapy/
The treatment landscape for multiple myeloma, a cancer of the bone marrow, looks very different now than it did just a decade ago. With the advent of immunotherapy, newly diagnosed patients now have better options for treatment. Recently, the immunotherapy drug daratumumab, which targets the CD38 protein on the surface of cancer cells, was

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619355/
Hematological cancers such as leukemia, lymphoma, and multiple myeloma have traditionally been treated with chemo and radiotherapy approaches. Introduction of immunotherapies for treatment of these diseases has led to patient remissions that would not

https://journals.lww.com/co-oncology/Abstract/2020/11000/Immunotherapy_in_multiple_myeloma__when,_where,.16.aspx
Immunotherapy is transforming treatment of multiple myeloma patients in all stages of their disease. This review will discuss recent developments in immunotherapy in multiple myeloma with a focus on antibodies, antibody-drug conjugates, and T-cell-redirection strategies.

https://www.cancerresearch.org/blog/march-2020/multiple-myeloma-awareness-2020-immunotherapy
Multiple Myeloma Webinar. In this webinar for patients and caregivers, Dr. Hearn Jay Cho of the Mt. Sinai School of Medicine discusses the latest research and developments in cancer immunotherapy for cancers of the blood, including leukemia, lymphoma, and multiple myeloma.

https://www.onclive.com/view/classes-of-immunotherapy-under-investigation-in-multiple-myeloma
Hearn Jay Cho, MD, PhD. In 2017, the FDA halted trials examining checkpoint inhibitors in multiple myeloma due to excess toxicity, which left an unclear role for this class of agents in this disease.

https://www.ajmc.com/view/revolutionizing-multiple-myeloma-immunotherapy-is-transforming-treatment-extending-lives-dr-mohamad-mohty-says
The CAR T cells were approved in multiple myeloma after approval of CAR T cells in lymphoma but also ALL [acute lymphoblastic leukemia]. Immunotherapy with bispecific antibodies, now we're

https://pubmed.ncbi.nlm.nih.gov/26338470/
Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem c

https://pubmed.ncbi.nlm.nih.gov/31427259/
The next generation of myeloma immunotherapy under investigation consists of T-cell-directed strategies designed to promote cytotoxic activity against myeloma cells, as embodied by chimeric antigen receptor-modified T cells (CAR-T) and bispecific T-cell-engaging agents.

https://cancer.umn.edu/news/u-m-opens-first-class-engineered-nk-cell-therapy-trial-treatment-patients-advanced-multiple
The University of Minnesota has become the first location in the world for a new innovative clinical trial for the treatment of acute myelogenous leukemia (AML) and multiple myeloma. The Phase 1 clinical trial for FT538 will eventually be a multicenter study but has initially opened exclusively at the M Health Fairview University of Minnesota Medical Center.

https://stage.cancerresearch.org/en-us/immunotherapy/cancer-types/multiple-myeloma
Immunotherapy for multiple myeloma is a promising new treatment option, with the potential to result in long-term cancer remission similar to the results of allogeneic bone marrow transplantation with less risk for complications.

https://www.news-medical.net/news/20231109/Tumor-immune-interactions-predict-treatment-responses-in-multiple-myeloma.aspx
A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune

https://cancerblog.mayoclinic.org/2024/06/18/fighting-lymphoma-treatment-options-include-alternatives-to-chemotherapy/
Dr. Stephen Ansell discusses research to develop new lymphoma therapies and the currently available nonchemotherapy treatment options.

https://www.mymyelomateam.com/resources/immunotherapy-for-multiple-myeloma-what-to-know
Traditionally, multiple myeloma treatment relies on chemotherapy drugs and radiation. However, new discoveries in the field of immunotherapy are now expanding treatment options for people living with myeloma. Immunotherapy modifies the immune system to target and fight cancer cells.

https://link.springer.com/article/10.1007/s12185-024-03793-1
The introduction of immunotherapies has led to remarkable progress in the treatment of hematological malignancies, including B-cell malignancies such as B-cell lymphoma and multiple myeloma (MM). Although conventional therapeutic antibodies are effective as immunotherapy for newly diagnosed and relapsed/refractory B-cell lymphoma and MM, some cases are resistant. Chimeric antigen receptor (CAR

https://www.curetoday.com/view/patients-with-multiple-myeloma-who-join-mmrfs-curecloud-may-improve-their-treatment-options-while-contributing-to-research
The Multiple Myeloma Research Foundation's newly launched CureCloud is a registry designed to collect clinical and genomic information about patients. Its goals are to help researchers discover treatments for various subtypes of the disease and let patients know whether they have any of 70 genetic aberrations associated with myeloma.